Omeprazole Krka (Omeprazole)

Omeprazole Krka is a proton pump inhibitor that acts on the gastric acid secretion pathway to treat several acid‑related conditions.

• Gastroesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of esophageal irritation.
• Peptic ulcer disease: supports ulcer healing by maintaining a low‑acid environment.
• NSAID‑induced gastric ulcer: reduces risk of ulcer formation and aids healing when NSAIDs are required.
• Helicobacter pylori eradication (in combination therapy): enhances the effectiveness of antibiotic regimens used to eradicate H. pylori infection.

• Omeprazole selectively inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By binding covalently to the pump’s cysteine residues, it blocks the final step of acid production, leading to a sustained reduction in gastric acidity and an elevated gastric pH.

Omeprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache
• Diarrhea
• Nausea
• Abdominal pain
• Flatulence
• Constipation

Serious or Rare Side Effects

• Clostridioides difficile infection
• Severe allergic reaction (anaphylaxis, angioedema)
• Low magnesium levels (hypomagnesemia)
• Bone fractures (with long‑term use)
• Acute interstitial nephritis
• Liver enzyme elevations

When using Omeprazole Krka, consider the following precautions:

• Assess renal function: adjust use in patients with severe renal impairment.
• Evaluate hepatic function: use with caution in moderate to severe liver disease.
• Monitor long‑term therapy: periodic assessment for vitamin B12 deficiency and bone health.
• Review concomitant medications: consider potential interactions with drugs that require an acidic environment for absorption.
• Pregnancy and lactation: discuss risks and benefits with a healthcare professional.
• Store at below 25°C: keep in the original container, protect from moisture and light.

Omeprazole can affect the plasma concentrations of several co‑administered medicines.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk.
• Atorvastatin: increased exposure, higher risk of myopathy.
• Methotrexate: elevated serum levels, potential toxicity.

Moderate Interactions (Monitor Closely)

• Warfarin: possible increase in INR, monitor coagulation parameters.
• Digoxin: altered absorption, check serum levels.
• Iron supplements: reduced absorption, separate dosing times.